0001140361-19-014501.txt : 20190910 0001140361-19-014501.hdr.sgml : 20190910 20190807215146 ACCESSION NUMBER: 0001140361-19-014501 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001338042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202960116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 500-7867 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc DATE OF NAME CHANGE: 20050906 CORRESP 1 filename1.htm
Aegerion Pharmaceuticals, Inc.
One Main Street, Suite 800
Cambridge, MA 02142

VIA EDGAR

August 7, 2019
 
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Mr. Jeffrey Gabor
 

 Re:
Aegerion Pharmaceuticals, Inc.
Form T-3 (File No. 022-29077)
 
Ladies and Gentlemen:
 
This letter is sent on behalf of Aegerion Pharmaceuticals, Inc. (the “Company”) and the co-applicants listed in the above-referenced Form T-3, as amended (the “Form T-3”) filed with the Securities and Exchange Commission (the “Commission”) by the Company and co-applicants pursuant to the Trust Indenture Act of 1939, as amended (the “TIA”).  Pursuant to the TIA, the Company, on behalf of itself and the co-applicants, hereby respectfully requests that the Form T-3 be declared eligible and qualified on or before 4:00pm, Eastern Time, on August 9, 2019 or as soon as practicable thereafter.

Very truly yours,

Aegerion Pharmaceuticals, Inc.

/s/ Barbara Chan
  
Barbara Chan
  
Director